Tocagen Inc. (NASDAQ:TOCA) was founded in August 2007 and is headquartered in San Diego, California, with 77 full-time employees. It is a clinical-stage biotechnology company in the United States, specializing in the development of gene therapy candidate products to activate the patient’s immune system , In order to avoid cancer invasion.
On June 15, 2020, Forte Biosciences, Inc. (NASDAQ:FBRX) , a clinical-stage biopharmaceutical company , announced the completion of its merger with Tocagen Inc. According to the merger, Forte’s shareholders have become Tocagen’s majority holders, and Tocagen shares Delisting. The company will be led by Dr. Paul Wagner. The newly merged company is called Forte Biosciences and will start trading on the Nasdaq Capital Market on June 16, 2020, under the trading code “FBRX”.
Tocagen Inc. (TOCA):
Tocagen is using its cancer selective gene therapy platform based on retroviral replicators (RRVs) (originally used for patients with relapsed hyperglioma (HGG)) to develop first-class, widely used cancer treatment candidates. Tocagen’s widely applicable product candidates are designed to activate the patient’s immune system from the inside to fight their own cancer (cells).
The core of Tocagen’s approach is the gene therapy platform using RRVs. RRV is designed to selectively (target) deliver therapeutic genes to the DNA of cancer cells. The company’s proprietary platform aims to fight cancer through a combination of mechanisms. Does not cause the patient’s autoimmune toxicity that is often associated with other treatment options. In other words, Tocagen’s technology aims to fight cancer with fewer side effects, while keeping the patient’s healthy tissues intact while the tumor (cell) is destroyed.
Tocagen is present in the patient. Tocagen’s hope is that even the most aggressive cancers can be safely and effectively controlled. Tocagen strives every day to turn this bold vision into reality.
Tocagen product candidates:
- Toca 511 & Toca FC-currently in the II/III clinical trials for the treatment of recurrent high-grade glioma (HGG); at the same time in the intravenous treatment of metastatic colorectal cancer, pancreatic cancer, breast cancer, lung cancer, melanoma and Kidney cancer Ib clinical trial stage; at the same time in the preclinical trial stage for the treatment of newly diagnosed HGG.
- Tocagen is also developing other retroviral replication vectors to deliver genes to cancer cells with proven immunotherapy targets such as the checkpoint protein PD-L1.
Tocagen Inc. (TOCA) investment:
Tocagen, Inc. (NASDAQ:TOCA) was listed on Nasdaq on 4/13/2017 IPO , with an issue price of US$10, 8.5 million shares issued, and US$85 million raised, stock code: TOCA.